- Home
- FNKO vs CVAC Comparison
FNKO vs CVAC Comparison
Compare FNKO & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNKO
- CVAC
- Stock Information
- Founded
- FNKO 2017
- CVAC 2000
- Country
- FNKO United States
- CVAC Germany
- Employees
- FNKO N/A
- CVAC N/A
- Industry
- FNKO Recreational Games/Products/Toys
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- FNKO Consumer Discretionary
- CVAC Health Care
- Exchange
- FNKO Nasdaq
- CVAC Nasdaq
- Market Cap
- FNKO 666.7M
- CVAC 637.1M
- IPO Year
- FNKO 2017
- CVAC 2020
- Fundamental
- Price
- FNKO $10.61
- CVAC $2.66
- Analyst Decision
- FNKO Strong Buy
- CVAC Hold
- Analyst Count
- FNKO 3
- CVAC 3
- Target Price
- FNKO $13.83
- CVAC $10.00
- AVG Volume (30 Days)
- FNKO 648.0K
- CVAC 576.1K
- Earning Date
- FNKO 11-07-2024
- CVAC 11-12-2024
- Dividend Yield
- FNKO N/A
- CVAC N/A
- EPS Growth
- FNKO N/A
- CVAC N/A
- EPS
- FNKO N/A
- CVAC N/A
- Revenue
- FNKO $1,047,357,000.00
- CVAC $70,565,734.00
- Revenue This Year
- FNKO N/A
- CVAC $123.97
- Revenue Next Year
- FNKO $7.50
- CVAC N/A
- P/E Ratio
- FNKO N/A
- CVAC N/A
- Revenue Growth
- FNKO N/A
- CVAC 75.11
- 52 Week Low
- FNKO $5.36
- CVAC $2.22
- 52 Week High
- FNKO $12.61
- CVAC $6.30
- Technical
- Relative Strength Index (RSI)
- FNKO 42.24
- CVAC 45.65
- Support Level
- FNKO $10.10
- CVAC $2.37
- Resistance Level
- FNKO $10.60
- CVAC $2.65
- Average True Range (ATR)
- FNKO 0.52
- CVAC 0.18
- MACD
- FNKO -0.06
- CVAC -0.01
- Stochastic Oscillator
- FNKO 27.11
- CVAC 48.33
About FNKO Funko Inc.
Funko Inc is an us-based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.